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Abstract
A rapid and accurate diagnosis of Clostridium difﬁcile infection (CDI) is essential for patient management and implementation of infection
control measures. During a prospective time-series study, we compared the impact of three different diagnostic strategies on patient care.
Each strategy was tested during a 3-month period: P1 (diagnosis based on the stool cytotoxicity assay and the toxigenic culture), P2
(diagnosis based on PCR) and P3 (two-step algorithm based on glutamate dehydrogenase detection followed by nucleic acid ampliﬁcation
test). The following criteria were used to assess the quality of patient management: (i) time for result reporting, (ii) frequency of repeat
testing within 7 days, (iii) time elapsed between stool collection and beginning of treatment for patients with CDI, and (iv) frequency of
empirical treatment for patients without CDI. Of 1122 stool samples (P1 n = 359, P2 n = 374, P3 n = 389), 36 (10.0%), 47 (12.3%) and 48
(12.3%) were positive for C. difﬁcile during P1, P2 and P3, respectively. The time for reporting of a positive or a negative result was
signiﬁcantly shorter and the frequency of redundant stool samples within 7 days was lower during P2 and P3 than during P1. Patients with
CDI were speciﬁcally treated with vancomycin or metronidazole earlier during P2 and P3 than patients from P1 (0.5  0.5 days and
1.0  1.8 days vs. 2.0  1.7 days). The empirical therapy among patients without CDI decreased from 13.6% during P1 to 6.4% during P2
and 5.6% during P3. A rapid CDI diagnosis impacts positively on patient care.
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Introduction
The epidemiology of Clostridium difﬁcile infection (CDI) has
dramatically changed over the last decade. Since 2003, many
outbreaks of severe CDI with high mortality rates have been
reported worldwide [1,2]. This situation coincided with the
emergence and the rapid dissemination of a previously
extremely rare genotype named BI/NAP1/027 [3,4]. Currently,
C. difﬁcile is recognized as the most frequent aetiological agent
of healthcare-associated diarrhoea in hospitalized adult
patients.
In this context, a rapid diagnosis of CDI is a key step in the
successful management of the disease. It enables the physician
to initiate treatment of the patient expeditiously and to
implement control measures rapidly to avoid cross-contami-
nation. Moreover, an accurate diagnosis is also essential to
obtain reliable data for surveillance, to assess the efﬁcacy of
intervention measures to reduce CDI, and to enable compar-
ison between institutions as part of performance management.
Currently there is no single ‘gold standard’ for the diagnosis of
CDI. The two reference methods often used for studies are
the stool cytotoxicity assay, which detects the presence of
‘free’ C. difﬁcile toxins in stool samples (primary toxin B but
also toxin A), and toxigenic culture, which detects C. difﬁcile
isolates in stool that have the potential to produce toxins. The
crucial question about the clinical signiﬁcance of the presence
of a toxigenic C. difﬁcile strain in the stool without any free
detectable toxin is still a matter of debate [5]. Both reference
methods are long, time-consuming and require 24–72 h to
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produce results. The recent changes in the epidemiology of
CDI have stimulated companies to ﬁnd more rapid and
sensitive methods for diagnosis. Since 2009, nucleic acid
ampliﬁcation tests based on the detection of either tcdA or
tcdB genes (which encode for toxins A and B, respectively)
have become commercially available. In addition, strategies
based on a two-step algorithm using the detection of glutamate
dehydrogenase (GDH) as a screening test followed by a
conﬁrmatory test for the GDH-positive stools were proposed
by the recent American and European guidelines [6,7].
However, the impact of these rapid methods on patient
management has not been evaluated.
The aim of the study was to assess the changes in patient
management after implementing a rapid diagnosis of CDI.
Materials and Methods
Hospital setting
This study was performed at Saint-Antoine hospital, which is a
public university-afﬁliated 750-bed hospital located in eastern
Paris. It provides emergency and acute-care services. Around
30 425 patients are admitted each year, corresponding to
221 711 days of hospitalization (data from 2011).
Clostridium difﬁcile testing is performed on physician’s
request and systematically for all diarrhoeic stool samples
prescribed after day 3 of hospitalization (corresponding to a
healthcare facility-onset, healthcare-associated diarrhoea). In
our hospital, repeated stool culture within a period of 7 days
following the initial C. difﬁcile test is systematically discarded
but is recorded in the microbiological database as an indicator
of quality. Patients with CDI are placed in a single room and
contact precautions are implemented according to a written
local procedure. Isolation measures are audited by the
infection control nurses during ward rounds.
Study design
A prospective study comparing three consecutive periods with
different CDI diagnosis strategies was undertaken. This study
was approved by the local committee for healthcare-associ-
ated infections.
All diarrhoeic stools (taking the shape of the container)
from adult inpatients with a clinical suspicion of CDI or a
healthcare-associated diarrhoea were included.
Stools samples from outpatients and from patients from
daycare centres were excluded.
During P1 (5December 2010 to 28 February 2011), diagnosis
of CDI was performed according to conventional reference
methods combining the stool cytotoxicity assay on MRC-5 cells
and the toxigenic culture, as previously described [8]. During P2
(1 March to 15May) and P3 (16 May to 15 August), the diagnosis
was performed using the Xpert C. difﬁcile assay (Cepheid,
Sunnyvale, CA, USA) and a two-step algorithm based on GDH
detection (QuikChek; Alere,Waltham,MA,USA) as a screening
test, followed by the Illumigene C. difﬁcile assay (Meridian
Bioscience, Cincinnati, OH, USA) on GDH-positive samples,
respectively. Stool samples were processed in a batch once a day
from Monday to Friday during P1 whereas they were tested on
demand from Monday to Saturday during P2 and P3. Xpert
C. difﬁcile, GDH detection and Illumigene C. difﬁcile assays were
performed according to the manufacturers’ instructions. To
assess sensitivity and speciﬁcity of the Xpert C. difﬁcile assay and
the two-step algorithm, toxigenic culture was systematically
performed on every stool sample during P2 and P3. Positive and
negative results of tests for C. difﬁcile from inpatients were
notiﬁed by telephone to the clinical service by medical resident
microbiologists. In case of positive toxigenic culture but negative
Xpert C. difﬁcile or two-step algorithm assays, the result was
transmitted to the clinician but excluded from the analysis of the
impact of a rapid diagnosis strategy on patient management.
An information letter was sent to every clinical ward to
inform clinicians about the changes of diagnosis strategy.
Data collection and analysis
For all patients tested for C. difﬁcile, the following data were
collected by medical microbiologists using a standardized
questionnaire: age, gender, ward, origin of the diarrhoea, date
of admission, date and hour of reception of stool sample at the
laboratory, date and hour of result notiﬁcation, date of initiation
of speciﬁc treatment by metronidazole or vancomycin, date of
implementation of isolation precautions, and date of discharge.
For patientswith a diagnosis ofCDI, clinical parameters (number
of stools per day, tenderness, abdominal pain) were recorded at
the day of stool culture. Outcome at day 10 (clinical cure, death)
and at day 30 (death or recurrent CDI) was assessed.
The following criteria were used to assess quality of patient
management:
1. time to receipt of results deﬁned as the time elapse between
stool reception at the laboratory and notiﬁcation of the
result to the clinician,
2. frequency of repeat testing within 7 days,
3. for patients with CDI: time elapse between stool collection
and beginning of treatment, length of hospital stay after CDI
diagnosis, mortality at day 10 and day 30
4. for patients without CDI: frequency and length of empirical
treatment for C. difﬁcile frequency and length of pre-emptive
contact precautions.
Patients who were on isolation precautions for another
reason or those who received intravenous metronidazole for
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another infection were not considered to be speciﬁcally
isolated or treated for their C. difﬁcile infection.
Data were entered into EPI INFO software (version 6.04dfr;
Centers for Disease Control and Prevention, Atlanta, GA,
USA). A chi-square analysis was used to compare categorical
variable and analysis of variance tests or the non-parametric
Mann–Whitney U test for variables with non-Gaussian distri-
bution were used to compare continuous variables. The
Bonferonni’s correction was used for multiple comparisons
(P1 vs. P2, P1 vs. P3 and P2 vs. P3). A two-sided p value <0.017
was considered statistically signiﬁcant.
Assessment of prescriber satisfaction
The clarity and rapidity of reporting was assessed through a
simple anonymous questionnaire sent to 30 senior and resident
prescribers from nine different wards at the end of periods 2 and
3. They were asked to rate their satisfaction on a quantitative
scale ranging from 0 (no satisfaction) to 10 (high satisfaction).
Deﬁnitions
Patients were considered to have CDI if they had a positive
test for C. difﬁcile (positive cytotoxicity assay, or toxigenic
culture or Xpert C. difﬁcile or GDH/Illumigene assays) or
evidence of pseudomembranes during lower endoscopy
examination. Healthcare-associated infection surveillance was
performed using the ECDC (Centers for Diseases Control and
Prevention) deﬁnitions [9].
A severe CDI case was deﬁned as a patient who meets any
of the following criteria: (i) history of admission to an intensive
care unit for complications associated with CDI (e.g. for shock
that requires vasopressor therapy); (ii) history of surgery (e.g.
colectomy) for toxic megacolon, perforation or refractory
colitis; or (iii) death caused by CDI within 30 days after
symptom onset [9].
Results
Between 5 December 2010 to 15 August 2011, 1122 stool
samples were tested for C. difﬁcile (Fig. 1) of which 130
(11.58%) were toxigenic culture-positive. The overall CDI
incidence during the entire study period was 8.18 cases CDI
per 10 000 patient-days. The CDI incidence did not differ
signiﬁcantly across the different periods but a slight increase in
incidence was observed after implementing rapid methods for
diagnosis (Table 1).
Compared with toxigenic culture as a reference method,
nine, two and three false-negative results were found with
P3
N = 389
340
negative
49 CDI
(12.6%)
45 GDH+/Illu+/TC+
2 GDH+Illu–/TC+
1 GDH–/TC+
1 PMC GDH–/Illu–/TC–
P2
N = 374
327
negative
47 CDI
(12.6%)
44 Xpert +/TC+
1 Xpert+/TC-
2 Xpert –/TC+
P1
N = 359
323
negative
36 CDI
(10.2%)
27 CTA +/TC+ 
9 CTA–/TC+
1122  
stool samples
FIG. 1. Flowchart of stool samples included in each study period and results of Clostridium difﬁcile testing. TC, toxigenic culture; CTA, stool
cytotoxicity assay; GDH, glutamate dehydrogenase; ILLU, Illumigene C. difﬁcile assay, Xpert, Xpert C. difﬁcile assay; PMC, pseudomembranous colitis;
CDI, C. difﬁcile infection.
TABLE 1. Incidence of Clostridium difﬁcile infection and density testing during each study period
Period 1 Period 2 Period 3 Total
p
(P1 vs. P2)
p
(P1 vs. P3)
p
(P2 vs. P3)
Total length of hospital stay (patient-days) 55 279 50 444 55 708 161 431
No. of stool samples tested 359 374 389 1122
Density of C. difﬁcile testing (/1000 patient-days) 6.49 7.41 6.98 6.95 0.07 0.32 0.63
No. of CDI 36 47 49 132
Incidence of CDI (per 10 000 patient-days) 6.51 9.32 8.80 8.18 0.10 0.16 0.85
No. of positive toxigenic cultures 36 46 48 130
Frequency of positive toxigenic cultures (/100 stool samples) 10.03 12.30 12.34 11.59 0.32 0.31 0.98
P1, period 1; P2, period 2; P3, period 3.
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cytotoxicity assay, Xpert C. difﬁcile and GDH/Illumigene algo-
rithm, respectively. In addition, we recorded one false-positive
result with the Xpert C. difﬁcile assay and none by cytotoxicity
assay or GDH/Illumigene algorithm. Sensitivity of cytotoxicity
assay, Xpert C. difﬁcile and two-step algorithm was 75% (95%
CI 57.46–87.27), 95.65% (95% CI 83.76–99.24) and 93.75%
(95% CI 81.79–98.37), respectively. Speciﬁcity was 100% (95%
CI 98.53–100), 99.69% (95% CI 98.84–99.98) and 100% (95%
CI 98.60–100), respectively.
Demographic data of patients (age, gender, origin of the
diarrhoea, wards) are described in Table 2 and were similar
across the three study periods. Changes in the management of
patients with a positive and a negative result are described in
Tables 3 and 4, respectively. Reporting of a positive or a negative
result was signiﬁcantly shorter in P2 and P3 compared with P1.
Frequency of redundant stool samples within 7 days was lower
during P2 and P3 compared with P1, whatever the initial result.
Treatment of patients with CDI with vancomycin or
metronidazole started earlier during P2 and P3 than during
P1 (0.5  0.5 days, 1.0  1.8 days vs. 2.0  1.7 days). Length
of hospital stay following the diagnosis of CDI was shorter in
patients from P2 to P3 compared with patients from P1 but the
difference was not statistically signiﬁcant (mean: 12.3 days and
12.5 days vs. 15.8 days, respectively). Empirical therapy among
patients without CDI decreased signiﬁcantly from 13.6%
during P1 to 6.4% during P2 and 5.6% during P3. Numbers
of unnecessary treatment-days were 243, 75 and 73 during P1,
P2 and P3, respectively.
When comparing the two periods with a rapid diagnosis (P2
and P3), the only statistically signiﬁcant difference was the time
restituer a positive result to the physician, which was shorter
for Xpert C. difﬁcile than for the two-step algorithm
(15.4  15.4 h vs. 31.4  38.7 h, respectively, p 0.004).
Clinicians reported being very satisﬁed with the rapidity of
the result return, whatever the strategy used (Xpert C. difﬁcile
or the two-step algorithm) (Fig. 2). Nevertheless they found
that clarity of reporting was better with Xpert C. difﬁcile than
with the two-step-algorithm (mean satisfaction rating 8.27 vs.
9.20, p 0.06).
Discussion
Accurate and early identiﬁcation of C. difﬁcile infections is a
crucial step for successfully treating patients and reducing
severe outcomes and complications. In addition, a rapid
diagnosis is also essential for implementing contact precautions
and preventing transmission of the organism from patient to
patient. Toxigenic culture and the stool cytotoxicity neutral-
ization assays are considered the reference methods but
paradoxically they are not frequently used in clinical labora-
tories in Europe. Two reasons for their low utilization are the
TABLE 2. Demographic features of patients included in each
study period
Period 1
(n = 359)
Period 2
(n = 374)
Period 3
(n = 389)
Age (years)
mean  SD (median)
59.8  20.2 (58) 58.6 + 20.0 (61) 57.0  20.0 (58)
Gender, female, n (%) 161 (44.8%) 186 (49.7%) 168 (43.2%)
Origin, n (%)
Healthcare
facility-onset,
healthcare
facility-associated
diarrhoea
177 (49.30%) 201 (54.18%) 186 (50.5%)
Community-onset,
healthcare
facility-associated
diarrhoea
43 (11.97%) 28 (7.54%) 28 (7.60%)
Community-
associated
diarrhoea
139 (38.71%) 142 (38.27%) 154 (42.66%)
Wards, n (%)
Digestive surgery 23 (6.4%) 30 (8.0%) 26 (6.7%)
Gastroenterology 88 (24.5%) 83 (22.2%) 64 (16.4%)
Haematology 76 (21.2%) 76 (20.3%) 75 (19.3%)
Hepatology 34 (9.5%) 36 (9.6%) 41 (10.5%)
Infectious diseases 18 (5.0%) 40 (10.7%) 39 (10.0%)
Internal medicine 24 (6.7%) 15 (4.0%) 24 (6.2%)
Oncology 16 (4.4%) 15 (4.0%) 17 (4.4%)
Medical intensive
care unit
42 (11.7%) 41 (10.9%) 48 (12.3%)
Other 38 (10.6%) 38 (10.2%) 55 (14.1%)
TABLE 3. Management of patient without Clostridium difﬁcile infection
Period 1
(CTA+TC)
(N = 323)
Period 2
(Xpert)
(N = 327)
Period 3
(GDH+Illu.)
(N = 340)
p
(P1 vs. P2)
p
(P1 vs. P3)
p
(P2 vs. P3)
Time for return of results
Days, mean  SD (median) 3.5  0.95 (3) 0.55  0.72 (0) 0.63  0.96 (0) <0.0001 <0.0001 0.57
Hours, mean  SD (median) 84.9  22.9 (75) 15.6  16.8 (4) 17.3  22.9 (6) <0.0001 0.0001 0.15
Redundant stool samples (<7 days), n (%) 68 (21.1%) 43 (13.3%) 52 (15.3%) 0.007 0.05 0.42
Empiric treatment by VA or MTZ, n (%) 44 (13.6%) 21 (6.4%) 19 (5.6%) 0.002 0.0004 0.64
Time to stop an empiric treatment (days)
mean  SD (median)
5.5  3.3 (4) 3.6  4.2 (2) 3.8  4.6 (2) 0.04 0.10 0.68
Number of unjustiﬁed treatment days 243 75 73
Contact precautions, n (%) 18 (5.6%) 10 (3.1%) 15 (4.4%) 0.11 0.48 0.36
Length of contact precautions (days) mean  SD (median) 4.5  1.8 (4) 4.7  6.8 (1.5) 3.7 + 3.6 (2) 0.043 0.08 0.93
Number of unjustiﬁed contact precautions days 82 47 55
CTA, cytotoxicity assay; GDH, glutamate dehydrogenase; MTZ, metronidazole; TC, toxigenic culture; VA, vancomycin.
P1, period 1; P2, period 2; P3, period 3.
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technical difﬁculty of performing the assays and their long
turnaround times. Enzyme immunoassays for toxins A and B
lack sensitivity and they should not be used as stand-alone
tests for the diagnosis of CDI according to recent European
and American guidelines [6,7]. The changes in the epidemiol-
ogy of CDI encouraged companies to ﬁnd new rapid and
sensitive methods for the diagnosis of CDI. Starting in 2009,
nucleic acid ampliﬁcation tests based on the detection of tcdA
or tcdB genes became commercially available. In clinical
practice, these methods are used either on every stool sample
or as a conﬁrmation method for stool samples that are positive
by GDH assays. However, these different strategies based on
nucleic acid ampliﬁcation tests are costly and their perfor-
mance and their impact on patient management should be
assessed before implementing them in a laboratory.
Our ﬁndings conﬁrm that PCR on every stool sample and a
two-step algorithm based on GDH detection followed by
conﬁrmation of positive results by Illumigene are both
sensitive methods for the diagnosis of CDI. These results
conﬁrm recent data that reported mean sensitivity and
speciﬁcity of PCR assays of 90% and 96%, respectively [10]
compared with toxigenic culture. The sensitivity of a
GDH-based algorithm is more controversial. On one hand,
these tests have displayed good correlation with culture on
selective medium. A recent meta-analysis of GDH tests
demonstrated a high diagnostic accuracy for the presence of
C. difﬁcile in faeces; when compared with culture, GDH tests
achieved a sensitivity of >90% [11]. On the other hand, a
recent report from Tenover et al. [12] suggested that the
performance of GDH assays depends upon the strain geno-
type, with a reduced sensitivity of the GDH assay for detecting
PCR ribotypes other than 027. However, this result was
challenged by a more recent study [13]. The objective of the
two-step algorithm based on GDH detection followed by
Illumigene is to save money compared with PCR performed
for every stool sample and to reduce the workload of cell
culture, PCR or toxigenic culture, which are often used as
conﬁrmatory tests [14].
During this study, we observed a slight, non-signiﬁcant
increase of CDI incidence following implementation of a rapid
diagnosis by PCR or the two-step algorithm. Recent studies
have shown that switching diagnostic strategy to nucleic acid
ampliﬁcation tests may lead to an excess rate of CDI [15,16].
This is particularly true when you move from a strategy that
lacks sensitivity (enzyme immunoassay for example) to nucleic
acid ampliﬁcation tests. Nevertheless, this is not the case in the
present study, where we showed that the sensitivity of PCR or
the two-step algorithm (GDH + Illumigene) compared with
the toxigenic culture (P1) was 95.6% and 93.7%, respectively.
Moreover, the increased CDI incidence observed during P2
and P3 was paradoxical because the incidence is usually higher
during winter months, which correspond to period P1 [17].
This trend may be explained by a higher density of C. difﬁcile
testing, indicating that the more you test, the more you ﬁnd, as
recently suggested [18]. Testing changes from 5 days a week
during P1 to 6 days a week during P2 and P3 may have
inﬂuenced ward practice and may have promoted C. difﬁcile
testing. This ﬁnding is also supported by the fact that patients
with CDI in P2 and P3 presented with less severe clinical
symptoms than in P1. Number of stools per day and
frequencies of tenderness and abdominal pain were lower in
CDI patients identiﬁed during P2 and P3, compared with
patients from P1. This observation suggests that a rapid
diagnosis may increase physicians’ trust in the results and can
TABLE 4. Management of patients with Clostridium difﬁcile infection
Period 1
(CTA+TC)
(n = 36)
Period 2
(Xpert)
(n = 45)
Period 3
(GDH+Illumig.)
(n = 45)
p
(P1 vs. P2)
p
(P1 vs. P3)
p
(P2 vs. P3)
Clinical presentation
Patients with  10 stools per day, n (%) 5 (14.7%) 6 (13.6%) 3 (6.7%) 0.57 0.23 0.31
Abdominal pain, n (%) 66 (72.2%) 29 (64.4%) 20 (44.4%) 0.45 0.01 0.06
Tenderness, n (%) 13 (36.1) 11 (24.4%) 7 (15.6%) 0.25 0.03 0.29
Time for return of results
Days, mean  SD (median) 3.1 + 2.58 (2) 0.53 + 0.66 (0) 1.20 + 1.64 (1) <0.0001 0.00015 0.013
Hours, mean  SD (median) 75.7 + 61.9 (51) 15.4 + 15.4 (5) 31.4 + 38.7 (27) <0.0001 0.00017 0.004
Redundant stool samples (<7 days), n (%) 13 (36.1%) 8 (17.8%) 2 (4.4%) 0.06 0.00026 0.04
Speciﬁc treatment by VA or MTZ, n (%) 29 (80.6%) 42 (93.3%) 38 (84.4%) 0.08 0.64 0.18
Time (days) elapse between C. difﬁcile testing
and speciﬁc treatment mean  SD (median)
2.00 + 1.68(2) 0.49 + 0.56 (0) 1.03 + 1.80 (0) <0.0001 0.039 0.43
Contact precautions, n (%) 29 (80.6%) 42 (93.3%) 34 (77.3%) 0.08 0.72 0.03
Clinical outcome
Clinical cure at day 10, n (%) 29 (85.3%) 43 (95.6%) 39 (90.7%) 0.11 0.46 0.36
Recurrence (within 30 days), n (%) 6 (17.6%) 6 (13.3%) 6 (14%) 0.59 0.65 0.93
Severity, n (%) 5 (14.7%) 2 (4.4%) 4 (9.3%) 0.11 0.46 0.37
Mortality at day 10, n (%) 5 (13.9%) 2 (4.4%) 5 (11.4%) 0.13 0.43 0.22
Mortality at day 30, n (%) 5 (13.9%) 5 (11.1%) 6 (13.3%) 0.70 0.59 0.74
LOS (days) mean  SD (median) 30.3  36.3 (19.5) 23.2  25.4 (15) 26.9  28.9 (20) 0.32 0.63 0.51
LOS after stool culture mean  SD (median) 15.8  14.0 (10.5) 12.3  19.7 (8) 12.5  12.5 (9) 0.05 0.27 0.51
CTA, cytotoxicity assay; GDH, glutamate dehydrogenase; LOS, length of stay; MTZ, metronidazole; TC, toxigenic culture; VA, vancomycin.
P1, period 1; P2, period 2; P3, period 3.
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potentially promote C. difﬁcile prescribing, even for patients
with very mild diarrhoea.
A key ﬁnding of this study is the positive impact of a rapid
diagnosis (PCR or two-step algorithm) on patient care
compared with conventional diagnosis based on stool cyto-
toxicity assay and toxigenic culture. Interestingly, there was no
signiﬁcant difference between the two rapid diagnostic strat-
egies, except for the time for return of a positive result.
First, the delay of result reporting (deﬁned as the interval
time between stool reception at the laboratory and the
notiﬁcation of the result) was shorter, both for positive and
negative results. This result was expected for two major
reasons: (i) PCR or GDH results can be obtained within a
working day, which is shorter than for the stool cytotoxicity
assay (24 h) or the toxigenic culture (48–72 h); in addition,
25% of CDI cases during P1 were only identiﬁed by toxigenic
culture, which accounts for a long delay in result reporting; (ii)
it has been possible to perform C. difﬁcile testing on demand
every day including Saturday during P2 and P3, because of the
simplicity of the techniques, which was not the case with the
cytotoxicity assay. The difference in the return of positive
results between P2 and P3 may be explained by the fact that
only the GDH test was reported to physicians on Friday
afternoon, conﬁrmation of GDH-positive results being per-
formed on the following Monday morning.
Second, the frequency of repeat testing decreased in P2 and
P3 compared with P1. This ﬁnding had no impact on cost
saving in our hospital, because redundant stool samples within
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FIG. 2. Assessment of clinicians’ satisfaction at the end of P2 (PCR) and P3 (two-step algorithm) regarding the rapidity (a) and clarity. (b) of result
reporting. A quantitative scale ranging from 0 (no satisfaction) to 10 (high satisfaction) was used to assess satisfaction.
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a 7-day period are recorded but not processed. Although
repeat testing is not recommended by different guidelines, it
remains a frequent practice in many healthcare facilities [19]. In
the case of an initial negative test, repeat testing will also
increase the likelihood of a false-positive result because of the
lack of speciﬁcity of the methods. In the case of an initial
positive test, repeat testing as a ‘test of cure’ may remain
positive for toxin or culture in 56% of patients despite
resolution of diarrhoea [20] and may lead to additional
unnecessary treatment. This practice may be encouraged by
delay in reporting results to the ward and induces extra costs.
Third, we found that the rate of patients speciﬁcally treated
by metronidazole or vancomycin was higher during P2 and P3
compared with P1 (93.3%, 84.4% vs. 80.6%), suggesting that
physicians considered that patients with a positive result by
PCR were truly infected. Fewer patients were treated with
vancomycin or metronidazole during P1, probably because the
results of toxigenic culture were returned, in some cases, after
the patients’ discharge. Moreover, patients with CDI were
treated more rapidly with metronidazole or vancomycin
during P2 and P3. Rapid awareness of positive microbiology
results on the part of healthcare professionals is essential for
quality patient care. Our ﬁndings strengthen the results from
Verdoorn et al. [21] who showed that telephone notiﬁcation
of test results for patients with CDI is associated with a
decreased time to the ordering of antimicrobial therapy. They
also showed that prolonged time to the ordering of antimi-
crobial therapy was associated with prolonged hospitalization.
We found that length of stay after a positive C. difﬁcile
diagnosis was shorter by 3.5 days when a PCR is used (p 0.05)
as a stand alone test and by 3.3 days (p 0.27) when a two-step
algorithm is used, compared with conventional diagnosis. In
addition, we also noticed that quicker treatment was associ-
ated with an overall decrease in recurrence rate, mortality at
day 10, and less severe outcome, but the difference did not
reach signiﬁcance, probably due to lack of statistical power.
A rapid diagnosis also had major positive consequences on
management of patients with negative results. We showed that
the rate of empiric treatment with metronidazole or vanco-
mycin decreased from P1 (13.4%) to P2 (6.4%) and P3 (5.6%),
as well as the number of unjustiﬁed contact precaution days.
All of these ﬁndings indicate that a rapid diagnosis improves
patient care and outcome and may result in considerable
savings to the hospital. These results are in agreement with
previous reports. Sewell et al. reported that a rapid CDI
diagnosis based on PCR impacts positively on patient care
compared with conventional diagnosis by the cytotoxicity
assay: patients were discharged earlier from hospital
(4.88 days for PCR-positive patients and 7.03 days for
PCR-negative patients) (Sewell B. et al., ESCMID 2012, P2274).
After implementing a PCR assay for C. difﬁcile, Loo et al.
showed that isolation days decreased by an average of 3–
4 days per patient, depending on the hospital (Loo V. et al.,
ICAAC 2011, D1273). Similarly, empirical therapy among
patients decreased from 29.1% to 10.9%. The high rate of
empirical therapy reported in their study may be explained by
the location of the facilities (Quebec) where the large
outbreaks of severe CDI due to the epidemic 027/BI/NAP1
strain were initially described in 2006 [22]. Cantazaro et al.
[23] showed that the switch from a toxin A/B enzyme
immunoassay to a PCR method for the diagnosis of CDI led to
a decrease of hospital onset healthcare-associated CDI (from
4.4 per 10 000 patient-days during enzyme immunoassay
testing to 0.9 per 10 000 patient-days during PCR testing).
They also found a signiﬁcant decrease in patient isolation days,
test ordered, and metronidazole usage for patients with
negative C. difﬁcile tests. However, these results were partly
explained by the changes in their infection control practices:
during the EIA period, patients with diarrhoea were placed in
pre-emptive isolation until three stool samples tested negative
for the presence of C. difﬁcile, whereas during the PCR period,
isolation was removed if a single negative PCR result for
toxigenic C. difﬁcile was obtained.
Although our main objective was not to perform a
health-economic study of a rapid CDI diagnosis, our results
represent valuable data that should be considered for further
cost-effectiveness studies or for ﬁnancial discussion with the
administrative decision makers. Larson et al. [24] conducted a
cost analysis study and showed that the increased cost of
either direct PCR testing or PCR testing as part of a three-step
algorithm was justiﬁed by the earlier detection of CDI cases,
which would prevent additional cases of nosocomial CDI and
shorten the length of stay of patients with CDI.
To our knowledge, this is the ﬁrst report showing an
increase of clinician satisfaction when a rapid diagnosis of CDI
is available. Clarity of reporting was considered higher with
PCR (binary answer: positive or negative) than with a two-step
algorithm where positive GDH result reporting may be
misinterpreted as a ﬁnal positive diagnosis. This ﬁnding
supports the idea that a rapid and reliable diagnostic test
increases clinicians’ trust in the results and can potentially
inﬂuence empirical CDI therapy and decrease unnecessary
antibiotic use, which represents a potential cost saving. It can
also help to optimize the use of private hospital rooms by
reliably identifying patients who do not have the disease.
The study has some limitations. First, it has been performed
in a single centre, and was neither blinded nor randomized. It is
therefore difﬁcult to extrapolate the results to other health-
care facilities with different modalities of management of
patients with CDI. Second, the frequency of patients with
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pre-emptive isolation precautions or empirical treatment was
probably underestimated because patients who were isolated
for another reason or those who were treated with intrave-
nous metronidazole for another infection were not taken into
account in the analysis. Third, we did not attempt to perform a
medico-economic analysis to estimate whether the decrease
of length of stay or repeat testing following rapid diagnosis may
compensate for the higher cost of PCR or a two-step
algorithm. However, with a daily cost of hospitalization
attributable to C. difﬁcile estimated to be between $1300 and
$2000 [25–27] and a number of CDI cases in our healthcare
facility of 150 per year, the PCR or two-step algorithm could
save more than $585 000 annually simply by reducing by
3 days the length of hospitalization of each patient with CDI.
Savings may be even more important if cost estimates take into
account technician time, which is reduced when using PCR or
two-step algorithm.
Conclusion
This study demonstrated that rapid C. difﬁcile testing by PCR
or a two-step algorithm impacts positively on patient manage-
ment by reducing empirical treatment, length of hospitaliza-
tion, and unnecessary repeat testing. It may also increase
clinicians’ satisfaction and their trust in laboratory results. All
these changes can potentially translate into cost savings for the
hospital.
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